ADC Therapeutics Overview
- Founded
- 2011

- Status
- Public
- Employees
- 149

- Stock Symbol
- ADCT

- Share Price
- $26.59
- (As of Friday Closing)
ADC Therapeutics General Information
Description
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Contact Information
- Biopole
- Route de la Corniche 3B
- 1066 Epalinges
- Switzerland
ADC Therapeutics Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$26.59 | $28.48 | $25.11 - $56.59 | $2.04B | 76.7M | 232K | -$3.89 |
ADC Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 2,131,782 | |||
Revenue | 0 | 2,340 | 1,140 | 1,803 |
EBITDA | (221,484) | (116,353) | (124,988) | (90,504) |
Net Income | (225,646) | (116,484) | (123,096) | (89,862) |
Total Assets | 521,526 | 137,682 | 150,558 | 271,949 |
Total Debt | 113,276 | 5,031 | 0 | 0 |
ADC Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.
Request a free trialADC Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.
Request a free trialADC Therapeutics Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialADC Therapeutics Competitors (58)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
BeiGene | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 00000000000 | 00.000 |
0000000 00000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000000 | 00.000 |
00000 000000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
00000 000000000000 | Formerly PE-Backed | Singapore, Singapore | 00 | 00000 | 000000000 | 00000 |
000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
ADC Therapeutics Executive Team (17)
ADC Therapeutics Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Barrie Ward Ph.D | Self | Board Member | 000 0000 |
Chris Martin Ph.D | ADC Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
Jacques Theurillat | Self | Board Member | 000 0000 |
Michael Forer | ADC Therapeutics | Vice Chairman | 000 0000 |
Peter Corr Ph.D | Auven Therapeutics | Chairman | 000 0000 |
ADC Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialADC Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.
Request a free trial